We are pleased to announce that as part of our rebranding strategy, our brand name has now changed from Anapharm Europe to Anapharm Bioanalytics.
Anapharm Europe is proud to announce that it has successfully undergone its first US FDA inspection at its Barcelona based bioanalytical lab.
Anapharm Europe is proud to announce that it has recently renewed its ANVISA (Brazil) certificate.
Anapharm Europe has renewed its certification to offer the advantages of the French research tax credit (crédit d’impôt recherche) for period 2015 – 2019.
Anapharm Biotech, the peptide and protein chemistry division of Anapharm Europe, has completed method development of biomarkers Anti-IIa, Anti-Xa and TPFI in human plasma by chromogenic assays and ELISA, respectively.
Anapharm Europe has improved the limit of quantification for analysis of Formoterol achieving a LLOQ of 0.2 pg/mL in Human Plasma.
Anapharm Europe has renewed once more its Certificate for Good Laboratory Practice Principles (GLP).
Anapharm Europe has renewed once more its Certificate for ANVISA (Brasil).
Anapharm Europe has updated the calibration range of its LC/MS/MS analytical method for Tiotropium achieving a limit of quantification of 0.2 pg/mL